3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
7
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Breast Neoplasms
3
Leukoplakia, Oral
2
Erythroplasia
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Prediabetic State
1
Posterior Fossa Ependymal Tumor
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms by Site
1
Mouth Neoplasms
1
Metabolic Diseases
1
Melanoma
1
Medulloblastoma
1
Insulin Resistance
1
Infertility
1
Hyperplasia
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Drug-drug Interaction,SHR3680
1
Interventions
pembrolizumab
27
Cisplatin
18
Cetuximab
12
Carboplatin
12
Surveys and Questionnaires
8
Radiotherapy
8
Paclitaxel
8
Docetaxel
6
Radiotherapy, Intensity-Modulated
5
Surgical Procedures, Operative
4
dostarlimab
3
Therapeutics
3
Standard of Care
3
Fluorouracil
3
Cyclophosphamide
3
Chemoradiotherapy
3
Blood Specimen Collection
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
nimotuzumab
2
fludarabine
2
durvalumab
2
atezolizumab
2
abemaciclib
2
X-Rays
2
Taxes
2
Radiosurgery
2
Radiation
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Metformin
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled